RecruitingNot Applicable

A Global Study of the PETAL Consortium

United States1,200 participantsStarted 2024-01-05

Plain-language summary

The goal of this observational study is to correlate molecular alterations with outcomes including overall survival (OS), progression-free survival (PFS), response rates for patients with a new diagnosis, primary refractory or relapse, of mature T-cell and NK-cell neoplasms (TNKL). We hypothesize that machine learning can be leveraged to uncover distinct genetic vulnerabilities that underlie treatment response and resistance for patients with TNKL, thus moving towards personalized treatment solutions.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Untreated, relapsed, or refractory histologically confirmed mature T-cell or NK-cell neoplasm. * All subtypes of PTCL are eligible except for T-cell large granular lymphocytic leukemia, cutaneous T-cell lymphoma such as but not limited to mycosis fungoides and transformation, Sézary syndrome, and primary cutaneous CD30+ disorders. Exclusion Criteria: * Precursor T/NK neoplasms, T-cell large granular lymphocytic leukemia, cutaneous T-cell lymphoma such as but not limited to mycosis fungoides and transformation, Sézary syndrome, and primary cutaneous CD30+ disorders. * Adults who are unable to consent, individuals who are not yet adults such as infants, children and teenagers, pregnant women, and prisoners.

What they're measuring

Overall Survival

Timeframe: Up to 4 Years

Progression-free Survival

Timeframe: Up to 4 Years

Duration of Response

Timeframe: Up to 4 Years

Time to progression

Timeframe: Up to 4 Years

Number of subjects proceeding to stem cell transplantation

Timeframe: Up to 4 Years

Association of tumor specific somatic variants with treatment response

Timeframe: Up to 4 Years

Trial details

NCT IDNCT06067347

SponsorMassachusetts General Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2028-01

Contact for this trial

Salvia Jain, MD

650-224-0183 salvia.jain@mgh.harvard.edu

View on ClinicalTrials.gov More T-Cell and NK-Cell Neoplasm trials

Plain-language summary

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Overall Survival

Timeframe: Up to 4 Years

Progression-free Survival

Timeframe: Up to 4 Years

Duration of Response

Timeframe: Up to 4 Years

Time to progression

Timeframe: Up to 4 Years

Number of subjects proceeding to stem cell transplantation

Timeframe: Up to 4 Years

Association of tumor specific somatic variants with treatment response

Timeframe: Up to 4 Years